Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Hughes · SciRah

Researcher profile · Semantic Scholar

B. Hughes

Share profile

B. Hughes — researcher profile on SciRah

h-index: 38
Works: 188
Citations: 7,974

Most-cited papers

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
K. Harrington, B. Burtness, R. Greil, D. Soulières +17 more
2022Journal of Clinical Oncology426 citations Open access
Semantic Scholar
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
J. Grob, R. Gonzalez, N. Basset-Seguin, O. Vornicova +10 more
2020Journal of Clinical Oncology257 citations Open access
Semantic Scholar
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
N. Gross, D. Miller, N. Khushalani, V. Divi +25 more
2022New England Journal of Medicine255 citations Open access
Semantic Scholar
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial.
B. Hughes, E. Muñoz-Couselo, L. Mortier, Å. Bratland +13 more
2021Annals of Oncology186 citations Open access
Semantic Scholar
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
B. Burtness, D. Rischin, R. Greil, D. Soulières +17 more
2022Journal of Clinical Oncology162 citations Open access
Semantic Scholar
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
D. Rischin, M. Migden, A. Lim, C. Schmults +24 more
2020Journal for ImmunoTherapy of Cancer162 citations Open access
Semantic Scholar
Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
L. Fong, A. Hotson, J. Powderly, M. Sznol +29 more
2019Cancer Discovery161 citations Open access
Semantic Scholar
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
A. Nowak, W. Lesterhuis, Peey-Sei Kok, Chris Brown +14 more
2020The Lancet Oncology143 citations Open access
Semantic Scholar
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.
Matthias G. Braun, Amelia Roman Aguilera, Ashmitha Sundarrajan, Dillon Corvino +45 more
2020Immunity142 citations Open access
Semantic Scholar
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
D. Rischin, K. Harrington, R. Greil, D. Soulières +16 more
2019Journal of Clinical Oncology119 citations
Semantic Scholar
Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group study.
D. Rischin, M. King, L. Kenny, S. Porceddu +13 more
2021International Journal of Radiation Oncology, Biology, Physics115 citations
Semantic Scholar
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
D. Rischin, N. Khushalani, C. Schmults, A. Guminski +20 more
2021Journal for ImmunoTherapy of Cancer104 citations Open access
Semantic Scholar
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
M. Brose, Yury Panaseykin, B. Konda, C. de la Fouchardiére +10 more
2021Journal of Clinical Endocrinology and Metabolism74 citations Open access
Semantic Scholar
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Elizabeth Ahern, B. Solomon, R. Hui, N. Pavlakis +2 more
2021Journal for ImmunoTherapy of Cancer64 citations Open access
Semantic Scholar
OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
A. Nowak, Peey-Sei Kok, W. Lesterhuis, B. Hughes +11 more
2018Journal of Thoracic Oncology40 citations Open access
Semantic Scholar
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
D. Rischin, K. Harrington, R. Greil, D. Soulières +19 more
2022Oral Oncology39 citations Open access
Semantic Scholar
Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma
Kai D. Tang, Sarju S. Vasani, Lilian Menezes, T. Taheri +6 more
2020Cancer Science38 citations Open access
Semantic Scholar
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
M. Alexander, N. Pavlakis, T. John, R. O'Connell +10 more
2020Lung Cancer38 citations
Semantic Scholar
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
J. L. Leal, M. Alexander, M. Itchins, Gavin Wright +8 more
2021Clinical Lung Cancer37 citations
Semantic Scholar
CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
N. Leighl, S. Laurie, G. Goss, B. Hughes +17 more
2021Journal of Thoracic Oncology35 citations Open access
Semantic Scholar
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.
D. Rischin, N. Khushalani, C. Schmults, A. Guminski +15 more
202033 citations
Semantic Scholar
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
Richard A. Miller, J. Luke, Shenshen Hu, S. Mahabhashyam +5 more
2022Journal for ImmunoTherapy of Cancer32 citations Open access
Semantic Scholar
An Occult HPV-Driven Oropharyngeal Squamous Cell Carcinoma Discovered Through a Saliva Test
Kai D. Tang, Sarju S. Vasani, T. Taheri, L. Walsh +3 more
2020Frontiers in Oncology32 citations Open access
Semantic Scholar
Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy
H. Sadeghirad, Ning Liu, J. Monkman, Ning Ma +12 more
2023Frontiers in Immunology31 citations Open access
Semantic Scholar
Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients
A. Kulasinghe, T. Taheri, K. O'Byrne, B. Hughes +2 more
2021Frontiers in Oncology29 citations Open access
Semantic Scholar
Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.
A. Guminski, A. Lim, N. Khushalani, C. Schmults +16 more
2019Journal of Clinical Oncology29 citations
Semantic Scholar
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
Elizabeth Ahern, A. Cubitt, E. Ballard, M. Teng +6 more
2019Trials27 citations Open access
Semantic Scholar
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial
Peey-Sei Kok, P. Forde, B. Hughes, Zhuo-Xin Sun +15 more
2022BMJ Open25 citations Open access
Semantic Scholar
Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).
L. Harshman, Michael P. Chu, S. George, B. Hughes +7 more
202025 citations
Semantic Scholar
CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
N. Leighl, S. Laurie, G. Goss, B. Hughes +15 more
202024 citations
Semantic Scholar
An update: circulating tumor cells in head and neck cancer
A. Kulasinghe, B. Hughes, L. Kenny, C. Punyadeera
2019Expert Review of Molecular Diagnostics24 citations Open access
Semantic Scholar
The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer
J. Turner, P. Yates, L. Kenny, L. Gordon +9 more
2019Supportive Care in Cancer23 citations Open access
Semantic Scholar
Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer
Joanna Kapeleris, Juliana Müller Bark, Shanon Ranjit, D. Irwin +8 more
2022Heliyon19 citations Open access
Semantic Scholar
Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment
E. Ahern, T. Brown, Louise Campbell, B. Hughes +4 more
2022British Journal of Nutrition19 citations Open access
Semantic Scholar
Application of circulating tumour cells to predict response to treatment in head and neck cancer
Xi Zhang, Chameera Ekanayake Weeramange, B. Hughes, Sarju S. Vasani +7 more
2022Cellular Oncology19 citations Open access
Semantic Scholar
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
K. Harrington, D. Rischin, R. Greil, D. Soulières +16 more
202019 citations
Semantic Scholar
Retrospective analysis of hospital admissions due to immune checkpoint inhibitor‐induced immune‐related adverse events (irAE)
Elizabeth Ahern, M. Allen, A. Schmidt, Zarnie Lwin +1 more
2020Asia-Pacific Journal of Clinical Oncology16 citations
Semantic Scholar
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer
J. Capdevila, A. Klochikhin, S. Leboulleux, P. Isaev +14 more
2022Thyroid15 citations Open access
Semantic Scholar
Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
B. Burtness, D. Rischin, R. Greil, D. Soulières +16 more
2020Bioinformatics, Convergence Science, and Systems Biology15 citations
Semantic Scholar
Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer
Gishan Ratnayake, M. Shanker, K. Roberts, R. Mason +6 more
2019Asia-Pacific Journal of Clinical Oncology15 citations
Semantic Scholar
A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma
Charles Lin, Trishna Ballah, M. Nottage, K. Hay +8 more
2021Radiation Oncology14 citations Open access
Semantic Scholar
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629
B. Hughes, R. G. Mendoza, N. Basset-Seguin, O. Vornicova +11 more
2021Dermatologic Therapy13 citations Open access
Semantic Scholar
Evaluation of a novel pre-treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy.
C. Blake, A. Edwards, E. Treleaven, T. Brown +5 more
2021Nutrition & Dietetics12 citations
Semantic Scholar
Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib
Sarah Chan, E. Ahern, Sarah Chaudhry, B. Hughes
2019BMJ Case Reports11 citations Open access
Semantic Scholar
LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC.
M. Alexander, Joe Q. Wei, S. Parakh, T. John +10 more
2023JTO Clinical and Research Reports10 citations Open access
Semantic Scholar
Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy
C. Blake, T. Brown, A. Pelecanos, Laura B Moroney +4 more
2022Head and Neck10 citations
Semantic Scholar
426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
M. Brose, Yury Panaseykin, B. Konda, C. Fouchardière +9 more
202010 citations Open access
Semantic Scholar
Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
D. Rischin, A. Lim, C. Schmults, N. Khushalani +15 more
2019Annals of Oncology10 citations Open access
Semantic Scholar
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).
A. Kulasinghe, C. O'Leary, J. Monkman, V. Bharti +6 more
2021Lung Cancer9 citations Open access
Semantic Scholar
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
P. Forde, A. Nowak, Peey-Sei Kok, C. Brown +14 more
2021Journal of Clinical Oncology9 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Rischin×13
Invite
D. Rischin — researcher profile on SciRah
L. Kenny×11
Invite
L. Kenny — researcher profile on SciRah
B. Gumuscu×8
Invite
B. Gumuscu — researcher profile on SciRah
N. Pavlakis×8
Invite
N. Pavlakis — researcher profile on SciRah

×8

Invite

K. O'Byrne — researcher profile on SciRah

Å. Bratland×7

Invite

Å. Bratland — researcher profile on SciRah

Invite

R. Swaby — researcher profile on SciRah

Invite

B. Burtness — researcher profile on SciRah

Invite

R. Greil — researcher profile on SciRah

D. Soulières×6

Invite

D. Soulières — researcher profile on SciRah

Invite

M. Tahara — researcher profile on SciRah

Invite

A. Psyrri — researcher profile on SciRah